All
UNC study uncovers potentially safer treatment for pemphigus vulgaris
September 6th 2006Chapel Hill, N.C. - University of North Carolina School of Medicine researchers say they may have found a safer, more effective way to treat the autoimmune skin disease pemphigus vulgaris (PV) without turning off the immune system.
Psoriasis study provides important insight into anti-inflammatory mechanism of TNF blockade
September 1st 2006Results from a clinical study investigating the in situ mechanism of action of etanercept (Enbrel, Amgen) in the treatment of psoriasis indicate this agent, which binds both tumor necrosis factor (TNF) and lymphotoxin, breaks the cycle of dendritic cell activation and maturation and thereby decreases T-cell activation and the production of a cascade of inflammatory mediators by multiple cell types, Alice B. Gottlieb, M.D., Ph.D., says.
Novel occlusive patch improves responses to topical psoriasis medications
September 1st 2006Interim results from an open-label controlled clinical study indicate that occlusion with a specially designed hydrogel patch safely and significantly enhances the efficacy of a variety of topical medications that are used in the treatment of psoriasis, reported researchers from the University of California at the American Academy of Dermatology's Summer Academy '06.
Nail psoriasis: biopsy, histopathology can aid diagnosis
September 1st 2006In cases of psoriasis affecting the nails but not the skin, nail biopsy and histopathology can potentially help patients avoid unnecessary treatments, according to a recent study (Grover C et al. Br J Dermatol. 2005 Dec;153(6):1153-1158).
Acupuncture combats chronic skin diseases
September 1st 2006Piscataway, N.J. - Modern medical acupuncture can help patients, particularly those with chronic skin diseases, improve their overall health and avoid risks associated with systemic treatments, says an expert who has experience with acupuncture both personally and professionally.
Phase 3 infliximab data show excellent initial responses
September 1st 2006Results from one year of follow-up in a phase 3 trial investigating infliximab (Remicade, Centocor) for the treatment of moderate-to-severe psoriasis demonstrate that the dramatic responses, achieved rapidly after induction therapy, are sustained with maintenance therapy in the majority of patients and without the emergence of new safety concerns, reported Alan Menter, M.D., at the American Academy of Dermatology's Academy '06.
Phase 4 study reaffirms safety of low-dose acitretin
September 1st 2006Results of a phase 4, open-label, multicenter study indicate that low-dose acitretin (Soriatane, Connetics) in moderate to severe psoriasis patients provides efficacy as monotherapy by 24 weeks, but requires patience, said Gerald G. Krueger, M.D., at the American Academy of Dermatology's Academy '06.
Target retirement funds offer new options for busy investors
September 1st 2006Every fund has to pay its managers and cover normal operating expenses. That's where the annual management fee comes in. Whatever the rate of return generated by the fund, it will be reduced by the amount of the annual fee.
Sculptra tips include enforcing 'Rule of Fives,' combining with temporary fillers
September 1st 2006National report - Poly-L-lactic acid filler Sculptra (Dermik) can offer some excellent long-term results in adding volume when patients have facial lipoatrophy, and Cherie Ditre, M.D., offers some key tips to further enhance successful use of the filler.